0.028378
0.000000
0.000000
0.000000
0.028378
0.000000
0.000000
0.000000
0.009556
0.00000
0.00000
0.00000
Yadav, M.K.
Leman, L.J.
Stout, C.D.
Ghadiri, M.R.
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
16
90.00
90.00
90.00
35.238
35.238
104.647
C3 H7 N O2
89.093
y
ALANINE
L-peptide linking
C6 H15 N4 O2 1
175.209
y
ARGININE
L-peptide linking
C4 H8 N2 O3
132.118
y
ASPARAGINE
L-peptide linking
C4 H7 N O4
133.103
y
ASPARTIC ACID
L-peptide linking
C3 H7 N O2 S
121.158
y
CYSTEINE
L-peptide linking
C5 H10 N2 O3
146.144
y
GLUTAMINE
L-peptide linking
C5 H9 N O4
147.129
y
GLUTAMIC ACID
L-peptide linking
C2 H5 N O2
75.067
y
GLYCINE
peptide linking
C6 H10 N3 O2 1
156.162
y
HISTIDINE
L-peptide linking
H2 O
18.015
WATER
non-polymer
C6 H13 N O2
131.173
y
ISOLEUCINE
L-peptide linking
C6 H13 N O2
131.173
y
LEUCINE
L-peptide linking
C6 H15 N2 O2 1
147.195
y
LYSINE
L-peptide linking
C5 H11 N O2 S
149.211
y
METHIONINE
L-peptide linking
C3 H7 N O3
105.093
y
SERINE
L-peptide linking
C9 H11 N O3
181.189
y
TYROSINE
L-peptide linking
C5 H11 N O2
117.146
y
VALINE
L-peptide linking
US
Biochemistry
BICHAW
0033
0006-2960
44
9723
10.1021/BI050742A
16008357
Structure-Based Engineering of Internal Cavities in Coiled-Coil Peptides
2005
1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
93.0
1
CONFOCAL
2004-05-29
NI FILTER
SINGLE WAVELENGTH
M
x-ray
1
1.5418
1.0
1.5418
ROTATING ANODE
RIGAKU RU200
PEPTIDE REACTED WITH IODOACETIMIDE TO YEILD THIOETHER FROM CYSTEINE. NOTE SHIFT IN TYROSINE POSITION FROM PDB ENTRY 1VZL
4020.829
GENERAL CONTROL PROTEIN GCN4
YES
2
syn
polymer
18.015
water
2
nat
water
AMINO ACID BIOSYNTHESIS REGULATORY PROTEIN, PLI E20C ACETIMIDE
no
no
RMKQIEDKLEEILSKLYHICNELARIKKLLGER
RMKQIEDKLEEILSKLYHICNELARIKKLLGER
A,B
polypeptide(L)
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
1
2
38.9
VAPOR DIFFUSION, HANGING DROP
10.00
HANGING DROP, 1UL OF 1MG/ML PEPTIDE IN WATER, 1UL 100MM CAPS, 30% PEG 400, PH 10.5.
database_PDB_rev
database_PDB_rev_record
exptl_crystal_grow
pdbx_database_proc
pdbx_database_status
repository
Initial release
Version format compliance
Version format compliance
Data collection
Experimental preparation
Other
1
0
2004-09-24
1
1
2011-05-08
1
2
2011-07-13
1
3
2019-05-08
_exptl_crystal_grow.method
_pdbx_database_status.recvd_author_approval
HELIX CAPPING IN THE GCN4 LEUCINE ZIPPER
GCN4 LEUCINE ZIPPER COMPLEXED WITH SPECIFIC ATF/CREB SITE DEOXYRIBONUCLEIC ACID
ATOMIC STRUCTURE OF THE ECTODOMAIN FROM HIV -1 GP41
THE STRUCTURE OF AN HIV-1 SPECIFIC CELL ENTRY INHIBITOR INCOMPLEX WITH THE HIV-1 GP41 TRIMERIC CORE
GCN4 LEUCINE ZIPPER CORE MUTANT P-LI
GCN4 LEUCINE ZIPPER CORE MUTANT P-LI
HUMAN VIMENTIN COIL 2B FRAGMENT LINKED TO GCN4 LEUCINE ZIPPER (Z2B)
CRYSTAL STRUCTURE OF C14LINKMID/IQN17: A CROSS-LINKED INHIBITOR OF HIV-1 ENTRY BOUND TO THE GP41 HYDROPHOBIC POCKET
GLYTM1BZIP: A CHIMERIC PEPTIDE MODEL OF THE N-TERMINUS OF ARAT SHORT ALPHA TROPOMYOSIN WITH THE N-TERMINUS ENCODED BYEXON 1B
COILED COIL TRIMER GCN4-PVLS SER AT BURIED D POSITION
GCN4-PVLT COILED-COIL TRIMER WITH THREONINE AT THE D(12)POSITION
GCN4-PVTL COILED-COIL TRIMER WITH THREONINE AT THE A(16)POSITION
GCN4-PVSL COILED-COIL TRIMER WITH SERINE AT THE A(16)POSITION
CRYSTAL STRUCTURE OF THE C-TERMINAL REGION OF STRIATEDMUSCLE ALPHA-TROPOMYOSIN AT 2.7 ANGSTROM RESOLUTION
PLACEMENT OF THE STRUCTURAL PROTEINS IN SINDBIS VIRUS
CRYSTAL STRUCTURE OF A ZIF23-GCN4 CHIMERA BOUND TO DNA
VISUALIZING AN UNSTABLE COILED COIL: THE CRYSTAL STRUCTUREOF AN N-TERMINAL SEGMENT OF THE SCALLOP MYOSIN ROD
CRYSTAL STRUCTURE OF GCN4-PIQ, A TRIMERIC COILED COIL WITH BURIED POLAR RESIDUES
GCN4-LEUCINE ZIPPER CORE MUTANT AS N16A TRIGONAL AUTOMATICSOLUTION
ANTIPARALLEL TRIMER OF GCN4-LEUCINE ZIPPER CORE MUTANT ASN16A TETRAGONAL AUTOMATIC SOLUTION
ANTIPARALLEL TRIMER OF GCN4-LEUCINE ZIPPER CORE MUTANT ASN16A TRIGONAL FORM
ANTIPARALLEL TRIMER OF GCN4-LEUCINE ZIPPER CORE MUTANT ASN16A TETRAGONAL FORM
GCN4-LEUCINE ZIPPER CORE MUTANT AS N16A COMPLEXED WITH BENZENE
TMZIP: A CHIMERIC PEPTIDE MODEL OF THE N- TERMINUS OF ALPHA TROPOMYOSIN, NMR, 15 STRUCTURES
CRYSTAL STRUCTURE OF B562RIL, A REDESIGNED FOUR HELIX BUNDLE
STRUCTURE BASED ENGINEERING OF INTERNAL MOLECULAR SURFACES OF FOUR HELIX BUNDLES
STRUCTURE BASED ENGINEERING OF INTERNAL MOLECULAR SURFACES OF FOUR HELIX BUNDLES
STRUCTURE BASED ENGINEERING OF INTERNAL MOLECULAR SURFACES OF FOUR HELIX BUNDLES
STRUCTURE BASED ENGINEERING OF INTERNAL MOLECULAR SURFACES OF FOUR HELIX BUNDLES
STRUCTURE BASED ENGINEERING OF INTERNAL MOLECULAR SURFACES OF FOUR HELIX BUNDLES
STRUCTURE BASED ENGINEERING OF INTERNAL MOLECULAR SURFACES OF FOUR HELIX BUNDLES
STRUCTURE BASED ENGINEERING OF INTERNAL MOLECULAR SURFACES OF FOUR HELIX BUNDLES
STRUCTURE BASED ENGINEERING OF INTERNAL MOLECULAR SURFACES OF FOUR HELIX BUNDLES
STRUCTURE BASED ENGINEERING OF INTERNAL MOLECULAR SURFACES OF FOUR HELIX BUNDLES
STRUCTURE BASED ENGINEERING OF INTERNAL MOLECULAR SURFACES OF FOUR HELIX BUNDLES
STRUCTURE BASED ENGINEERING OF INTERNAL MOLECULAR SURFACES OF FOUR HELIX BUNDLES
STRUCTURE BASED ENGINEERING OF INTERNAL MOLECULAR SURFACES OF FOUR HELIX BUNDLES
STRUCTURE BASED ENGINEERING OF INTERNAL MOLECULAR SURFACES OF FOUR HELIX BUNDLES
AN ANTI-PARALLEL FOUR HELIX BUNDLE MUTANT PLI-E20C
GCN4 (BASIC REGION, LEUCINE ZIPPER) COMPLEX WITH AP-1 DEOXYRIBONUCLEIC ACID
GCN4-LEUCINE ZIPPER CORE MUTANT ASN16ABA IN THE DIMERIC STATE
GCN4-LEUCINE ZIPPER CORE MUTANT ASN16ABA IN THE TRIMERIC STATE
GCN4-LEUCINE ZIPPER CORE MUTANT ASN16LYS IN THE DIMERIC STATE
GCN4-LEUCINE ZIPPER CORE MUTANT ASN16GLN IN THE DIMERIC STATE
GCN4-LEUCINE ZIPPER CORE MUTANT ASN16GLN IN THE TRIMERIC STATE
LEUCINE ZIPPER MONOMER (NMR, 20 STRUCTURES)
GCN4 BASIC DOMAIN, LEUCINE ZIPPER COMPLEXED WITH ATF/CREB SITE DEOXYRIBONUCLEIC ACID
GCN4 LEUCINE ZIPPER
AN ANTI-PARALLEL FOUR HELIX BUNDLE.
AN ANTI-PARALLEL FOUR HELIX BUNDLE
AN ANTI-PARALLEL FOUR HELIX BUNDLE
ABA DOES NOT AFFECT TOPOLOGY OF PLI.
AN ANTI-PARALLEL TO PARALLEL SWITCH.
PDBE
Y
PDBE
2004-08-06
REL
HOH
water
4932
BAKER'S YEAST
SACCHAROMYCES CEREVISIAE
sample
CHAIN A, B ENGINEERED MUTATION GLU 268 CYS
THE N-TERMINUS OF THIS PEPTIDE IS ACETYLATED.
HOH
2001
2
HOH
HOH
2001
A
HOH
2001
2
HOH
HOH
2001
B
ARG
1
n
1
ARG
1
A
MET
2
n
2
MET
2
A
LYS
3
n
3
LYS
3
A
GLN
4
n
4
GLN
4
A
ILE
5
n
5
ILE
5
A
GLU
6
n
6
GLU
6
A
ASP
7
n
7
ASP
7
A
LYS
8
n
8
LYS
8
A
LEU
9
n
9
LEU
9
A
GLU
10
n
10
GLU
10
A
GLU
11
n
11
GLU
11
A
ILE
12
n
12
ILE
12
A
LEU
13
n
13
LEU
13
A
SER
14
n
14
SER
14
A
LYS
15
n
15
LYS
15
A
LEU
16
n
16
LEU
16
A
TYR
17
n
17
TYR
17
A
HIS
18
n
18
HIS
18
A
ILE
19
n
19
ILE
19
A
CYS
20
n
20
CYS
20
A
ASN
21
n
21
ASN
21
A
GLU
22
n
22
GLU
22
A
LEU
23
n
23
LEU
23
A
ALA
24
n
24
ALA
24
A
ARG
25
n
25
ARG
25
A
ILE
26
n
26
ILE
26
A
LYS
27
n
27
LYS
27
A
LYS
28
n
28
LYS
28
A
LEU
29
n
29
LEU
29
A
LEU
30
n
30
LEU
30
A
GLY
31
n
31
GLY
31
A
GLU
32
n
32
GLU
32
A
n
33
33
A
ARG
1
n
1
ARG
1
B
MET
2
n
2
MET
2
B
LYS
3
n
3
LYS
3
B
GLN
4
n
4
GLN
4
B
ILE
5
n
5
ILE
5
B
GLU
6
n
6
GLU
6
B
ASP
7
n
7
ASP
7
B
LYS
8
n
8
LYS
8
B
LEU
9
n
9
LEU
9
B
GLU
10
n
10
GLU
10
B
GLU
11
n
11
GLU
11
B
ILE
12
n
12
ILE
12
B
LEU
13
n
13
LEU
13
B
SER
14
n
14
SER
14
B
LYS
15
n
15
LYS
15
B
LEU
16
n
16
LEU
16
B
TYR
17
n
17
TYR
17
B
HIS
18
n
18
HIS
18
B
ILE
19
n
19
ILE
19
B
CYS
20
n
20
CYS
20
B
ASN
21
n
21
ASN
21
B
GLU
22
n
22
GLU
22
B
LEU
23
n
23
LEU
23
B
ALA
24
n
24
ALA
24
B
ARG
25
n
25
ARG
25
B
ILE
26
n
26
ILE
26
B
LYS
27
n
27
LYS
27
B
LYS
28
n
28
LYS
28
B
LEU
29
n
29
LEU
29
B
LEU
30
n
30
LEU
30
B
GLY
31
n
31
GLY
31
B
GLU
32
n
32
GLU
32
B
ARG
33
n
33
ARG
33
B
author_and_software_defined_assembly
PISA
4
tetrameric
5550
-85.99
7120
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
x,y,z
identity operation
0.0000000000
0.0000000000
0.0000000000
-1.0000000000
0.0000000000
0.0000000000
0.0000000000
-1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
2_765
-x+2,-y+1,z
crystal symmetry operation
70.4760000000
35.2380000000
0.0000000000
1
A
N
ARG
1
A
N
ARG
1
1
Y
1
A
CA
ARG
1
A
CA
ARG
1
1
Y
1
A
CB
ARG
1
A
CB
ARG
1
1
Y
1
A
CG
ARG
1
A
CG
ARG
1
1
Y
1
A
CD
ARG
1
A
CD
ARG
1
1
Y
1
A
NE
ARG
1
A
NE
ARG
1
1
Y
1
A
CZ
ARG
1
A
CZ
ARG
1
1
Y
1
A
NH1
ARG
1
A
NH1
ARG
1
1
Y
1
A
NH2
ARG
1
A
NH2
ARG
1
1
Y
1
A
CD
LYS
3
A
CD
LYS
3
1
Y
1
A
CE
LYS
3
A
CE
LYS
3
1
Y
1
A
NZ
LYS
3
A
NZ
LYS
3
1
Y
1
A
CG
GLN
4
A
CG
GLN
4
1
Y
1
A
CD
GLN
4
A
CD
GLN
4
1
Y
1
A
OE1
GLN
4
A
OE1
GLN
4
1
Y
1
A
NE2
GLN
4
A
NE2
GLN
4
1
Y
1
A
CG
GLU
6
A
CG
GLU
6
1
Y
1
A
CD
GLU
6
A
CD
GLU
6
1
Y
1
A
OE1
GLU
6
A
OE1
GLU
6
1
Y
1
A
OE2
GLU
6
A
OE2
GLU
6
1
Y
1
A
CE
LYS
8
A
CE
LYS
8
1
Y
1
A
NZ
LYS
8
A
NZ
LYS
8
1
Y
1
A
CD
GLU
22
A
CD
GLU
22
1
Y
1
A
OE1
GLU
22
A
OE1
GLU
22
1
Y
1
A
OE2
GLU
22
A
OE2
GLU
22
1
Y
1
B
CD
ARG
1
B
CD
ARG
1
1
Y
1
B
NE
ARG
1
B
NE
ARG
1
1
Y
1
B
CZ
ARG
1
B
CZ
ARG
1
1
Y
1
B
NH1
ARG
1
B
NH1
ARG
1
1
Y
1
B
NH2
ARG
1
B
NH2
ARG
1
1
Y
1
B
CG
GLN
4
B
CG
GLN
4
1
Y
1
B
CD
GLN
4
B
CD
GLN
4
1
Y
1
B
OE1
GLN
4
B
OE1
GLN
4
1
Y
1
B
NE2
GLN
4
B
NE2
GLN
4
1
Y
1
B
CD
GLU
6
B
CD
GLU
6
1
Y
1
B
OE1
GLU
6
B
OE1
GLU
6
1
Y
1
B
OE2
GLU
6
B
OE2
GLU
6
1
Y
1
B
CD
GLU
10
B
CD
GLU
10
1
Y
1
B
OE1
GLU
10
B
OE1
GLU
10
1
Y
1
B
OE2
GLU
10
B
OE2
GLU
10
1
Y
1
B
CD
ARG
25
B
CD
ARG
25
1
Y
1
B
NE
ARG
25
B
NE
ARG
25
1
Y
1
B
CZ
ARG
25
B
CZ
ARG
25
1
Y
1
B
NH1
ARG
25
B
NH1
ARG
25
1
Y
1
B
NH2
ARG
25
B
NH2
ARG
25
1
Y
1
B
CG
LYS
28
B
CG
LYS
28
1
Y
1
B
CD
LYS
28
B
CD
LYS
28
1
Y
1
B
CE
LYS
28
B
CE
LYS
28
1
Y
1
B
NZ
LYS
28
B
NZ
LYS
28
1
Y
1
B
CB
ARG
33
B
CB
ARG
33
1
Y
1
B
CG
ARG
33
B
CG
ARG
33
1
Y
1
B
CD
ARG
33
B
CD
ARG
33
1
Y
1
B
NE
ARG
33
B
NE
ARG
33
1
Y
1
B
CZ
ARG
33
B
CZ
ARG
33
1
Y
1
B
NH1
ARG
33
B
NH1
ARG
33
1
Y
1
B
NH2
ARG
33
B
NH2
ARG
33
1
Y
1
A
ARG
33
A
ARG
33
1
Y
40.43
1.16000
0.00000
0.00000
1.16000
0.00000
-2.32000
0.881
0.853
HYDROGENS HAVE BEEN ADDED IN THE RIDING POSITIONS.
0.337
0.304
0.305
2.16
51.99
176
3754
4.500
99.4
6.182
0.166
RANDOM
1
THROUGHOUT
MOLECULAR REPLACEMENT
0.351
0.269
0.80
0.80
1.40
MAXIMUM LIKELIHOOD
BABINET MODEL WITH MASK
2.16
51.99
2
493
0
0
491
0.018
0.021
493
0.002
0.020
494
1.526
2.026
655
0.876
3.000
1145
4.729
5.000
62
0.068
0.200
81
0.006
0.020
510
0.004
0.020
79
0.209
0.200
154
0.218
0.200
505
0.194
0.200
470
0.285
0.200
3
0.205
0.200
11
0.286
0.200
34
0.020
0.200
1
0.891
1.500
317
1.655
2.000
501
2.437
3.000
176
4.093
4.500
154
0.2820
0.2290
2.22
10
268
20
2.160
34.880
1W5G
3960
2.000
0.05000
1
17.3000
5.370
100.0
0.22000
2.16
2.24
6.500
1
5.01
97.6
refinement
REFMAC
5.1.24
data reduction
CrystalClear
(MSC/RIGAKU)
data scaling
CrystalClear
(MSC/RIGAKU)
phasing
MOLREP
GENERAL CONTROL PROTEIN GCN4
An anti-parallel four helix bundle (acetimide modification).
1
N
N
1
N
N
2
N
N
2
N
N
A
MET
2
A
MET
2
HELX_P
A
GLU
32
A
GLU
32
1
1
31
B
ARG
1
B
ARG
1
HELX_P
B
ARG
33
B
ARG
33
1
2
33
STRUCTURAL PROTEIN
STRUCTURAL PROTEIN, FOUR HELIX BUNDLE, ANTIPARALLEL FOUR HELIX BUNDLE
GCN4_YEAST
UNP
1
P03069
249
281
1W5G
1
33
P03069
A
1
1
33
249
281
1W5G
1
33
P03069
B
1
1
33
1
LEU
conflict
ILE
5
1W5G
A
P03069
UNP
253
5
1
LEU
conflict
ILE
12
1W5G
A
P03069
UNP
260
12
1
ASN
conflict
LEU
16
1W5G
A
P03069
UNP
264
16
1
LEU
conflict
ILE
19
1W5G
A
P03069
UNP
267
19
1
GLU
engineered mutation
CYS
20
1W5G
A
P03069
UNP
268
20
1
VAL
conflict
LEU
23
1W5G
A
P03069
UNP
271
23
1
LEU
conflict
ILE
26
1W5G
A
P03069
UNP
274
26
1
VAL
conflict
LEU
30
1W5G
A
P03069
UNP
278
30
2
LEU
conflict
ILE
5
1W5G
B
P03069
UNP
253
5
2
LEU
conflict
ILE
12
1W5G
B
P03069
UNP
260
12
2
ASN
conflict
LEU
16
1W5G
B
P03069
UNP
264
16
2
LEU
conflict
ILE
19
1W5G
B
P03069
UNP
267
19
2
GLU
engineered mutation
CYS
20
1W5G
B
P03069
UNP
268
20
2
VAL
conflict
LEU
23
1W5G
B
P03069
UNP
271
23
2
LEU
conflict
ILE
26
1W5G
B
P03069
UNP
274
26
2
VAL
conflict
LEU
30
1W5G
B
P03069
UNP
278
30
94
P 42 21 2